---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019977"
form_type: "8-K/A"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T07:39:32.080743+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MannKind Q1 2023 revenues jump 239% to $41M; loss from ops down 72%

## Summary
- Total revenues $40.6M, +239% vs Q1 2022; Tyvaso DPI contributed $23M (services + royalties).
- Afrezza net revenue $12.4M (+26% YoY); V-Go added $5.1M after Q2 2022 acquisition.
- Loss from operations narrowed 72% to $6M; commercial product gross margin 69%.
- Cash and investments $166.6M at March 31, 2023; R&D spend up to $5.6M for pipeline.
- CEO cites strong Tyvaso DPI demand; Phase 2/3 inhaled clofazimine trial planned H2 2023.

## SEC filing metadata
- accession: 0000950170-23-019977
- form_type: 8-K/A
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01, 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000095017023019977/0000950170-23-019977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000095017023019977/mnkd-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019977
- JSON: https://secwatch.observer/filing/0000950170-23-019977.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019977.txt

## Key facts
- Earnings Releases
  MANNKIND CORP reported the quarter ended March 31, 2023 results: revenue $41 million.
  - Period: the quarter ended March 31, 2023
  - Revenue: $41 million
  - Result: reported results
  source text: 1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/899460/000095017023019977/0000950170-23-019977-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.